检索结果 - Jennifer G. Robinson
- Showing 1 - 20 results of 97
- Go to Next Page
-
1
-
2
-
3
Safety of Aggressive Lipid Management 由 Michael H. Davidson, Jennifer G. Robinson
出版 2007Revisão -
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosu... 由 Jennifer G. Robinson, Helen M. Colhoun, Harold Bays, Peter H. Jones, Yunling Du, Corinne Hanotin, Stephen Donahue
出版 2014Artigo -
13
-
14
-
15
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODY... 由 Dean J. Kereiakes, Jennifer G. Robinson, Christopher P. Cannon, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun
出版 2015Artigo -
16
-
17
-
18
-
19
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data 由 Naveed Sattar, David Preiss, Jennifer G. Robinson, C. Stephen Djedjos, Mary Elliott, Ransi Somaratne, Scott M. Wasserman, Frederick J. Raal
出版 2016Revisão -
20
相关主题
Medicine
Internal medicine
Cholesterol
Endocrinology
Biology
Confidence interval
Pathology
Lipoprotein
Disease
Hazard ratio
Cardiology
Diabetes mellitus
Proportional hazards model
LDL receptor
PCSK9
Statin
Alternative medicine
Apolipoprotein A1
Environmental health
Genetics
Placebo
Biochemistry
Ezetimibe
Sociology
Alirocumab
Randomized controlled trial
Cohort
Demography
Gastroenterology
Gene